Crossmark

A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis

Crossref DOI link: https://doi.org/10.1186/s12969-019-0355-0

Published Online: 2019-07-25

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bava, Cecilia http://orcid.org/0000-0002-5545-2501
Mongelli, Federica

Pistorio, Angela

Bertamino, Marta

Bracciolini, Giulia

Dalprà, Sara

Davì, Sergio

Lanni, Stefano

Muratore, Valentina

Pederzoli, Silvia

Rosina, Silvia

Schiappapietra, Benedetta

Suffia, Chiara

Varnier, Giulia

Verazza, Sara

Giancane, Gabriella

Consolaro, Alessandro

Ravelli, Angelo
License Information

Text and Data Mining valid from 2019-07-25

Version of Record valid from 2019-07-25
More Information

Article History

Received: 12 March 2019

Accepted: 16 July 2019

First Online: 25 July 2019

Ethics approval and consent to participate

: The study protocol was approved by the ethics committee of the Istituto G. Gaslini, Genoa, Italy.

: Not applicable.

: AR has received grant support and/or speaking or consultant fees from Alfa sigma, Angelini, AbbVie, Bristol-Myers Squibb, Novartis, Pfizer, Reckitt Benckiser, Roche, and Johnson & Johnson; AC reports personal fees from AbbVie and Alfasigma and non-financial support from Pfizer.

Document is current

Any future updates will be listed below